Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

Executive Summary

'Believe it or not, we don't have as many disease-specific guidances as you would suspect on the new drug side,' Commissioner Gottlieb says.

Advertisement

Related Content

US FDA To Publish Own Datasets In Latest Signal Of Enhanced Transparency
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
Woodcock Wants Rapid Regulatory Policy Development
CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS121541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel